Clinical trials: High-Grade Cervical Intraepithelial Neoplasia
Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia
Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection
In this prospective paired diagnostic study and single-center, randomized controlled trial, patients with early esophageal squamous neoplasia or high-grade intraepithelial neoplasia meeting the inclusion and exclusion criteria…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia, AI-Based Dissection Trajectory Prediction System
- Trial name
- NCT07757906
- Testing
- AI-based Dissection Trajectory Prediction System (ADTPS), Conventional ESD Procedure
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Qilu Hospital of Shandong University
High-grade Squamous Intraepithelial Lesions (HSIL), Cervical Conization
Predicting Treatment Failure in HSIL Patients with Positive Margins After Conization Via Detection of PAX1 Methylation
The goal of this multicenter, observational study is to evaluate whether methylation testing of paired box gene 1 (PAX1) can better predict and diagnose recurrence or persistent disease in patients with positive margins after…
- Trial name
- NCT06713655
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women.
- Conditions
- High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion, ASC-US, HPV Infection
- Trial name
- NCT07572396
- Testing
- EGCG and Quinine Sulfate Vaginal Suppository
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- Amplexd Therapeutics, Inc.